CAS 183319-69-9

Erlotinib hydrochloride

Description:

Erlotinib hydrochloride is a small molecule tyrosine kinase inhibitor primarily used in the treatment of non-small cell lung cancer and pancreatic cancer. It specifically targets the epidermal growth factor receptor (EGFR), inhibiting its activity and thereby blocking the signaling pathways that promote tumor growth and survival. The compound is typically administered orally and is known for its ability to penetrate the blood-brain barrier, making it effective for certain brain metastases. Erlotinib hydrochloride is characterized by its solubility in water due to the presence of the hydrochloride salt, which enhances its bioavailability. The molecular formula reflects its complex structure, which includes a quinazoline core. Common side effects associated with its use include skin rash, diarrhea, and potential liver enzyme elevation. As with many targeted therapies, the effectiveness of erlotinib can be influenced by the presence of specific mutations in the EGFR gene, making genetic testing an important consideration in treatment planning. Overall, erlotinib hydrochloride represents a significant advancement in personalized cancer therapy.

Formula: C₂₂H₂₄ClN₃O₄

InChI: InChI=1/C22H23N3O4.ClH/c1-4-16-5-7-17(8-6-16)25-22-18-13-20(28-11-9-26-2)21(29-12-10-27-3)14-19(18)23-15-24-22;/h1,5-8,13-15H,9-12H2,2-3H3,(H,23,24,25);1H

InChI key: InChIKey=GTTBEUCJPZQMDZ-UHFFFAOYSA-N

SMILES: N(C=1C2=C(C=C(OCCOC)C(OCCOC)=C2)N=CN1)C3=CC(C#C)=CC=C3.Cl

Synonyms:

• 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, hydrochloride (1:1)
• 4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monohydrochloride
• 6,7-Bis(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline hydrochloride
• Cp 358774
• Erlotinib HCl
• Erlotinib Hcl Salt
• Erlotinib, Hydrochloride Salt
• Erlotinib, OS-774
• N-(2-chloro-6-methyl-phenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methyl-pyrimidin-4-yl]amino]thiazole-5-carboxamide
• N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4- Hydrochloride
• N-(3-Ethynylphenyl)-6,7-bis-(2-methoxyethoxy)-quinazolin-4-amine Hydrochloride
• N-(3-Ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine hydrochloride
• N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
• N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine hydrochloride (1:1)
• N-(4-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine hydrochloride (1:1)
• Osi 774
• Tarceva
• [6,7-Bis(2-methoxyethoxy)quinazolin-4-yl]-(3-ethynylphenyl)amine hydrochloride
• [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4yl]-(3-ethynyl-phenyl)-amine
• quinazolinamine, Hydrochloride Salt, OSI 774, Tarceva
• Tarceva Hydrochloride See E625000
• Erlotinib HCl(TINIBS)
• Erlotinib hydrochloride
• ERLOTINIB
• 6,7-BIS(2-METHOXYETHOXY)-4-(3-ETHYNYLANILINO)QUINAZOLINE HCL
• ERLOTINIB HCL SALT :TARCEVA
• erlotinib hydorchloride
• N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, Hydrochloride Salt, OSI 774, Tarceva
• 21 Erlotinib hydrochloride and Intermediate
• Tarceva HydrochlorideSee E625000
• Erlotonid HCl

Erlotinib Hydrochloride

CAS: 183319-69-9

Formula: C₂₂H₂₃N₃O₄·HCl

Purity: >98.0%(T)(HPLC)

Color and Shape: White to Light yellow powder to crystal

Molecular weight: 429.90

Ref: 3B-E1404

Erlotinib Hydrochloride

CAS: 183319-69-9

Drugs containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure

Formula: C₂₂H₂₃N₃O₄·HCl

Color and Shape: Pale Yellow Powder

Molecular weight: 429.14553

Ref: 45-1241608

Erlotinib hydrochloride

CAS: 183319-69-9

Erlotinib hydrochloride (NSC 718781) is an EGFR inhibitor (IC50: 2 nM). It is used for the treatment of non-small cell lung cancer.

Formula: C₂₂H₂₃N₃O₄·HCl

Purity: 99.78% - 99.85%

Color and Shape: White Or Off-White Powder

Molecular weight: 429.9

Ref: TM-T0373L

4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, hydrochloride (1:1)

CAS: 183319-69-9

Formula: C₂₂H₂₃ClN₃O₄

Purity: 98%

Color and Shape: Solid

Molecular weight: 429.8967

Ref: IN-DA0027I4

Erlotinib Hydrochloride Salt

CAS: 183319-69-9

Erlotinib Hydrochloride Salt

Formula: C₂₂H₂₃N₃O₄·ClH

Purity: By hplc: 99.9% by area (Typical Value in Batch COA)

Color and Shape: white to off-white crystalline solid

Molecular weight: 429.90g/mol

Ref: 54-BIFK0020

Erlotinib hydrochloride

CAS: 183319-69-9

Erlotinib hydrochloride

Purity: ≥98%

Molecular weight: 429.9g/mol

Ref: 54-BUP17066

Erlotinib hydrochloride

CAS: 183319-69-9

Formula: C₂₂H₂₃N₃O₄·HCl

Purity: ≥ 98.0% (dried basis)

Color and Shape: White to off-white powder

Molecular weight: 429.90

Ref: 7W-GP3306

Erlotinib HCl

CAS: 183319-69-9

Formula: C₂₂H₂₃N₃O₄·HCl

Color and Shape: White To Off-White Solid

Molecular weight: 393.44 36.46

Ref: 4Z-E-281

Erlotinib Hydrochloride

Controlled Product

CAS: 183319-69-9

Formula: C₂₂H₂₃N₃O₄·ClH

Color and Shape: Neat

Molecular weight: 429.90

Ref: 86-MM3297.00

Erlotinib hydrochloride

CAS: 183319-69-9

Formula: C₂₂H₂₄ClN₃O₄

Purity: 98%

Color and Shape: Solid, Crystalline Powder

Molecular weight: 429.9

Ref: 10-F036497

Erlotinib Impurity 95

CAS: 183319-69-9

Formula: C₁₄H₈ClN₃O₂

Molecular weight: 285.69

Ref: 4Z-E-28118

Tarceva (Erlotinib Hydrochloride)

Controlled Product

CAS: 183319-69-9

Applications Selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor. Antineoplastic.
References Moyer, J.D., et al.: Cancer Res., 57, 4838 (1997), Hidalgo, M., et al.: J. Clin. Oncol., 19, 3267 (2001), Perez-Soler, R., et al.: J. Clin. Oncol., 22, 3238 (2004), Blackhall, F.H., et al.: Expert Opin. Pharmacother., 6, 995 (2005),

Formula: C₂₂H₂₃N₃O₄·ClH

Color and Shape: Neat

Molecular weight: 429.90

Ref: TR-T007500

Erlotinib Hydrochloride (Tarceva)

Controlled Product

CAS: 183319-69-9

Applications Selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor. Antineoplastic.
References Moyer, J.D., et al.: Cancer Res., 57, 4838 (1997), Hidalgo, M., et al.: J. Clin. Oncol., 19, 3267 (2001), Perez-Soler, R., et al.: J. Clin. Oncol., 22, 3238 (2004), Blackhall, F.H., et al.: Expert Opin. Pharmacother., 6, 995 (2005),

Formula: C₂₂H₂₃N₃O₄·ClH

Color and Shape: White To Light Yellow

Molecular weight: 429.90

Ref: TR-E625000

Erlotinib HCl

CAS: 183319-69-9

Tyrosine kinase inhibitor; affects EGFR receptor; pancreatic cancer treatment

Formula: C₂₂H₂₃N₃O₄·HCl

Purity: Min. 98 Area-%

Color and Shape: Powder

Molecular weight: 429.9 g/mol

Ref: 3D-FE10803

Erlotinib hydrochloride - Bio-X ™

CAS: 183319-69-9

Erlotinib is a drug that is used to treat human malignancies. It is a type of kinase inhibitor that inhibits the EGFR tyrosine kinase, preventing the activation of downstream signalling pathways. Erlotinib has been shown to be effective in treating squamous cell carcinoma, melanoma, and other types of skin cancer. Additionally, Erlotinib has potential for use as an anti-inflammatory agent in the treatment of psoriasis and ulcerative colitis.

Formula: C₂₂H₂₃N₃O₄·HCl

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 429.9 g/mol

Ref: 3D-BE164421